B72.3 - Revision history

Michael at 22:24, 22 January 2019

2019-01-22T22:24:02Z

← Older revision		Revision as of 22:24, 22 January 2019
Line 11:		Line 11:
	\| Subspecial =		\| Subspecial =
	\| Pattern = cytoplasmic		\| Pattern = cytoplasmic
	\| Positive = [[malignant mesothelioma]]		\| Positive = most carcinomas
	~~\| Negative = most carcinomas~~		\| Negative = [[malignant mesothelioma]]
	\| Other =		\| Other =
	}}		}}

Michael: /* Use */

2019-01-22T22:23:46Z

Use

← Older revision		Revision as of 22:23, 22 January 2019
Line 18:		Line 18:

	==Use==		==Use==
			===Negative===
			*[[Mesothelioma]] - stains ~3% (6 of 196<ref name=pmid29048219/>).

	===Positive===		===Positive===
	*~~[[Mesothelioma]]~~		*Most carcinomas.<ref name=pmid1866206>{{Cite journal \| last1 = Betta \| first1 = PG. \| last2 = Pavesi \| first2 = M. \| last3 = Pastormerlo \| first3 = M. \| last4 = Tallarida \| first4 = F. \| last5 = Bellingeri \| first5 = D. \| last6 = Bocca \| first6 = R. \| title = Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions. \| journal = Pathologica \| volume = 83 \| issue = 1083 \| pages = 99-104 \| month = \| year = \| doi = \| PMID = 1866206 }}</ref>

	===~~Negative~~===
	*Most carcinoma - ~~stains ~3% (6 of 196~~<ref ~~name=pmid29048219/~~>).

	==See also==		==See also==

Michael at 22:15, 22 January 2019

2019-01-22T22:15:26Z

← Older revision		Revision as of 22:15, 22 January 2019
Line 8:		Line 8:
	\| Similar =		\| Similar =
	\| Clones =		\| Clones =
	\| Use =		\| Use = mesothelioma versus carcinoma
	\| Subspecial =		\| Subspecial =
	\| Pattern = cytoplasmic		\| Pattern = cytoplasmic

Michael: create

2019-01-22T22:14:18Z

create

New page

{{ Infobox immunostain
| Name = {{PAGENAME}}
| Image =
| Width =
| Caption =
| Abbrev =
| Synonyms =
| Similar =
| Clones =
| Use =
| Subspecial =
| Pattern = cytoplasmic
| Positive = [[malignant mesothelioma]]
| Negative = most carcinomas
| Other =
}}
'''B72.3''' in an [[immunostain]] useful in the diagnosis of [[malignant mesothelioma]].<ref name=pmid29048219>{{Cite journal | last1 = Tandon | first1 = RT. | last2 = Jimenez-Cortez | first2 = Y. | last3 = Taub | first3 = R. | last4 = Borczuk | first4 = AC. | title = Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases. | journal = Arch Pathol Lab Med | volume = 142 | issue = 2 | pages = 236-242 | month = Feb | year = 2018 | doi = 10.5858/arpa.2017-0092-OA | PMID = 29048219 }}</ref>

==Use==
===Positive===
*[[Mesothelioma]]

===Negative===
*Most carcinoma - stains ~3% (6 of 196<ref name=pmid29048219/>).

==See also==
*[[Malignant mesothelioma]].

==References==
{{Reflist|1}}

[[Category:Immunohistochemistry]]